Pyrimethamine: Difference between revisions
| Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
'''Pyrimethamine''' (trade name '''Daraprim''') is a [[medication]] used for [[protozoal]] infections. It is commonly used as an [[antimalarial drug]] (for both treatment and prevention of [[malaria]]), and is also used (combined with [[sulfadiazine]]) in the treatment of ''[[Toxoplasma gondii]]'' infections in [[immunocompromise]]d patients, such as [[HIV]]-positive individuals. It is also currently being evaluated<ref>{{cite web|title=Pyrimethamine ALS trial|url=http://clinicaltrials.gov/ct2/show/NCT01083667}}</ref> in clinical trials as a treatment for [[ALS]]. In 2011, researchers have discovered that Pyrimethamine can increase ß-hexosaminidase activity, thus slowing down the progression of Late-Onset [[Tay–Sachs]] disease. | '''Pyrimethamine''' (trade name '''Daraprim''') is a [[medication]] used for [[protozoal]] infections. It is commonly used as an [[antimalarial drug]] (for both treatment and prevention of [[malaria]]), and is also used (combined with [[sulfadiazine]]) in the treatment of ''[[Toxoplasma gondii]]'' infections in [[immunocompromise]]d patients, such as [[HIV]]-positive individuals. It is also currently being evaluated<ref>{{cite web|title=Pyrimethamine ALS trial|url=http://clinicaltrials.gov/ct2/show/NCT01083667}}</ref> in clinical trials as a treatment for [[ALS]]. In 2011, researchers have discovered that Pyrimethamine can increase ß-hexosaminidase activity, thus slowing down the progression of Late-Onset [[Tay–Sachs]] disease. | ||
==References== | ==References== | ||
Revision as of 21:01, 9 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Overview
Pyrimethamine (trade name Daraprim) is a medication used for protozoal infections. It is commonly used as an antimalarial drug (for both treatment and prevention of malaria), and is also used (combined with sulfadiazine) in the treatment of Toxoplasma gondii infections in immunocompromised patients, such as HIV-positive individuals. It is also currently being evaluated[1] in clinical trials as a treatment for ALS. In 2011, researchers have discovered that Pyrimethamine can increase ß-hexosaminidase activity, thus slowing down the progression of Late-Onset Tay–Sachs disease.
References
Adapted from the FDA Package Insert.
Category
US Brand Names
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages